Vera Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGVera Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 55), indicating performance broadly in line with the market. Earnings contraction of 109% provides fundamental context to the price action. Investors should exercise caution due to high volatility (93% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $39.13 | -8.31% | BELOW |
| 50 SMA | $39.72 | -9.68% | BELOW |
| 100 SMA | $43.20 | -16.94% | BELOW |
| 150 SMA | $39.32 | -8.75% | BELOW |
| 200 SMA | $35.28 | +1.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VERA in an uptrend right now?
VERA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is VERA overbought or oversold?
VERA's RSI (14) is 41. The stock is in neutral territory, neither overbought nor oversold.
Is VERA outperforming the market?
VERA has a Relative Strength (RS) Rating of 55 out of 99. VERA is performing about average compared to the market.
Where is VERA in its 52-week range?
VERA is trading at $35.88, which is 64% of its 52-week high ($56.05) and 46% above its 52-week low ($18.76).
How volatile is VERA?
VERA has a Beta of 1.35 and 52-week volatility of 93%. It's more volatile than the S&P 500 - expect bigger swings.